American journal of preventive cardiology最新文献

{"title":"Systematic examination of the PREVENT equations for cardiovascular disease risk","authors":"Vaishnavi Krishnan ,&nbsp;Xiaoning Huang ,&nbsp;Chiadi E. Ndumele ,&nbsp;Janani Rangaswami ,&nbsp;Josef Coresh ,&nbsp;Amanda M. Perak ,&nbsp;Nilay S. Shah ,&nbsp;Donald M. Lloyd-Jones ,&nbsp;Sadiya S. Khan","doi":"10.1016/j.ajpc.2026.101502","DOIUrl":"10.1016/j.ajpc.2026.101502","url":null,"abstract":"<div><h3>Background</h3><div>The Predicting Risk of cardiovascular disease (CVD) EVENTs (PREVENT) equations accurately estimate CVD risk, but how different combinations of ages and risk factors translate into risk estimates, including combinations required to meet clinically meaningful risk thresholds, is not intuitive.</div></div><div><h3>Methods</h3><div>We calculated sex-specific estimatesion of 10-year risk of total CVD (composite of atherosclerotic CVD and heart failure) for a hypothetical person between the ages of 30–79 years with the PREVENT-CVD base equations and varied individual or multiple risk factors simultaneously, with all other risk factor levels set at sex-specific, population-based average values. Next, we examined how specific age and risk factor combinations would exceed clinically-meaningful thresholds. Secondary analyses included the PREVENT-CVD equations with add-on predictors and the 30-year PREVENT-CVD equations.</div></div><div><h3>Results</h3><div>Ten-year risk estimates for a hypothetical person with average risk factor levels ranged from 0.3 %-17.4 % for a female and 0.7 %-22.8 % for a male with the PREVENT-CVD base equations, exceeding the clinically-relevant risk threshold of ≥7.5 % at age 68 years if female and at age 63 years if male. Additionally, a hypothetical person with Stage 3 CKD and diabetes would exceed the 10-year risk threshold of ≥7.5 % with the PREVENT-CVD equations at age 43 years if female and at age 36 years if male. Similar patterns were observed with add-on predictor equations. With average risk factor levels, 30-year PREVENT-CVD risk estimates ranged from 2.5 %-20.5 % for a female and 4.8 %-26.5 % for a male.</div></div><div><h3>Conclusions</h3><div>These results can support clinicians and patients in the interpretability of the PREVENT equations and can inform clinician-patient discussions on preventive efforts.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101502"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Lipoprotein(a) and diet quality with cardiovascular disease risk: the multi-ethnic study of atherosclerosis","authors":"Amier Haidar ,&nbsp;Harveen K. Sekhon ,&nbsp;Rishi Rikhi ,&nbsp;Karol E. Watson ,&nbsp;Michael D. Shapiro","doi":"10.1016/j.ajpc.2026.101627","DOIUrl":"10.1016/j.ajpc.2026.101627","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101627"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time in target systolic blood pressure range and cardiometabolic disease–free life expectancy in hypertensive elderly","authors":"Liuxin Li ,&nbsp;Jingdi Zhang ,&nbsp;Huixin Yu ,&nbsp;Yiran Xu ,&nbsp;Zheng Ma ,&nbsp;Gang Zheng ,&nbsp;Tiantian Liu ,&nbsp;Jingyuan Jiang ,&nbsp;Shouling Wu ,&nbsp;Yang Xia ,&nbsp;Yuhong Zhao","doi":"10.1016/j.ajpc.2026.101430","DOIUrl":"10.1016/j.ajpc.2026.101430","url":null,"abstract":"<div><h3>Background</h3><div>Although sustained blood pressure control is known to reduce cardiovascular and renal events, its long-term impact on overall life expectancy and the proportion of life lived free from cardiometabolic disease (CMD) remains insufficiently quantified.</div></div><div><h3>Aims</h3><div>To examine the associations between systolic blood pressure time in target range (SBP-TTR) and total life expectancy, CMD-free life expectancy, and life expectancy lived with CMD among adults with hypertension.</div></div><div><h3>Methods</h3><div>This prospective cohort study included 18,503 adults aged ≥45 years with hypertension from the Kailuan Study (China), followed from 2006 to 2022. SBP-TTR (120–140 mmHg) was assessed over a 6-year exposure period. Multistate life table models were applied to estimate total, CMD-free, and CMD-lived life expectancy across SBP-TTR categories.</div></div><div><h3>Results</h3><div>During a mean follow-up of 11.94 years, 7,393 incident CMD events were identified, including 1,443 deaths after CMD onset. Estimated CMD-free life expectancy increased progressively across SBP-TTR categories, from 38.77 years (95% CI: 38.50–39.05) in the low group to 40.29 years (95% CI: 40.19–40.23) in the high group. Compared with low SBP-TTR, high SBP-TTR was associated with 1.51 additional years of total life expectancy and 6.18 additional CMD-free years, alongside a 4.67-year reduction in CMD-lived life expectancy. Early blood pressure control conferred greater benefits than later control.</div></div><div><h3>Conclusion</h3><div>Higher SBP-TTR is associated with longer life expectancy and, importantly, a greater proportion of life lived free from CMD, supporting SBP-TTR as a clinically meaningful metric for long-term hypertension management.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101430"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease","authors":"Stefan D. Anker ,&nbsp;Linong Ji ,&nbsp;Tammy Kindel ,&nbsp;Andrew J.S. Coats ,&nbsp;Dike Ojji ,&nbsp;Adriana Puente Barragán ,&nbsp;Peter Rossing ,&nbsp;Shelley Zieroth ,&nbsp;Shaaf Ahmad ,&nbsp;Shariq Usman ,&nbsp;Geeta Appannah ,&nbsp;Alison L. Bailey ,&nbsp;Ahmed Bennis ,&nbsp;Andrea Brandao ,&nbsp;Javed Butler ,&nbsp;Melanie J. Davies ,&nbsp;Lubomira Fabryova ,&nbsp;Yuan-Lin Guo ,&nbsp;Hidetaka Itoh ,&nbsp;Uday M. Jadhav ,&nbsp;Jose Luis Zamorano","doi":"10.1016/j.ajpc.2026.101445","DOIUrl":"10.1016/j.ajpc.2026.101445","url":null,"abstract":"<div><div>There are a number of guidelines on how to manage obesity, but inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices restrict their global applicability. This underscores the need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our Global Guidelines emphasize the incorporation of novel therapies, while integrating standards of care with the most up-to-date evidence to enable clinicians to optimize obesity management. Context-specific recommendations tailored to individual patient needs are highlighted, providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that improves patient outcomes and reduces the burden of hospitalization in this susceptible population. These Global Guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guidelines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged, and – most importantly – also provide recommendations on several issues where resource limitations may put constraints on the care provided to patients living with obesity. Such “economic adjustment” recommendations aim to guide situations when “Resources are somewhat limited” or when “Resources are severely limited”. Hence, this document presents a comprehensive update to obesity management guidelines, thereby aiming to provide a unified strategy for the pharmacological, non-pharmacological, and invasive management of this significant global health challenge that is applicable to the needs of healthcare around the globe.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101445"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE – primary prevention study","authors":"Kim G. Smolderen ,&nbsp;Carlos Mena-Hurtado ,&nbsp;Victoria Divino ,&nbsp;Zhenxiang Zhao ,&nbsp;Yan Chen ,&nbsp;Joanna Boland ,&nbsp;Ariel Chao ,&nbsp;Jinlin Song ,&nbsp;B. Gabriel Smolarz ,&nbsp;Filip K. Knop ,&nbsp;Michael G. Nanna","doi":"10.1016/j.ajpc.2026.101521","DOIUrl":"10.1016/j.ajpc.2026.101521","url":null,"abstract":"<div><h3>Background</h3><div>Semaglutide 2.4 mg is approved for the secondary prevention of major adverse cardiovascular events (MACE) among individuals with overweight/obesity. We investigated its association with MACE among individuals with overweight/obesity without diabetes who had risk factors for atherosclerotic cardiovascular disease (ASCVD) in the real-world setting.</div></div><div><h3>Methods</h3><div>Adults (≥45 years) with overweight/obesity and ≥3 risk factors for ASCVD but without diabetes were identified from a U.S. database (01/01/2016–12/31/2024). Patients initiating semaglutide 2.4 mg were propensity-score matched 1:2 to those not on semaglutide 2.4 mg. The primary outcomes included revised 3-point MACE (rMACE-3: myocardial infarction, stroke, and all-cause mortality) and revised 5-point MACE (rMACE-5: rMACE-3, coronary revascularization, and hospitalization for heart failure [HF]). Secondary outcomes included MACE-3 and MACE-5 (replacing all-cause mortality with cardiovascular-related mortality), and HF composite outcomes.</div></div><div><h3>Results</h3><div>A total of 48,184 individuals on semaglutide 2.4 mg were matched to 96,368 individuals not on semaglutide 2.4 mg; patient characteristics were well-balanced between cohorts. Semaglutide 2.4 mg was associated with lower risks of rMACE-3 (HR: 0.59; <em>p</em> &lt; 0.001), rMACE-5 (HR: 0.65; <em>p</em> &lt; 0.001), MACE-3 (HR: 0.73; <em>p</em> &lt; 0.01), MACE-5 (HR: 0.75; <em>p</em> &lt; 0.01), and composite HF outcomes over a mean follow-up of 9 months.</div></div><div><h3>Conclusions</h3><div>Semaglutide 2.4 mg was associated with lower risk of incident MACE and HF composite outcomes in this real-world study of patients with overweight/obesity without diabetes, who were at risk for developing ASCVD. Further research is warranted to confirm the role of semaglutide 2.4 mg in the primary prevention of ASCVD in this population.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101521"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between ADHD history and “Life’s Crucial 9” cardiovascular risk factors in young adults","authors":"Na Li ,&nbsp;Meiyuan Chen ,&nbsp;Sidong Li ,&nbsp;Yang Du ,&nbsp;Yuxiao Wu ,&nbsp;Xiaodong Zang ,&nbsp;Ruishu Zhang ,&nbsp;Zihan Zhang ,&nbsp;Buyun Liu ,&nbsp;Wei Bao ,&nbsp;Guifeng Xu","doi":"10.1016/j.ajpc.2026.101636","DOIUrl":"10.1016/j.ajpc.2026.101636","url":null,"abstract":"<div><h3>Objective</h3><div>Symptoms of attention-deficit/hyperactivity disorder (ADHD) often persist into adulthood, increasing cardiovascular disease (CVD) risk. This study extends our previous research, by examining associations between ADHD and modifiable CVD risk factors, incorporating the recently proposed Life's Crucial 9 (LC9) metric.</div></div><div><h3>Methods</h3><div>We conducted a prospective analysis using data from the National Longitudinal Study of Adolescent to Adult Health (Add Health). ADHD was identified at Wave IV (mean age 28.4), and at Wave V (approximately 9 years later), we assessed nine CVD risk components, including smoking, physical activity, diet, sleep, body mass index, lipids, blood glucose, blood pressure, and psychological health status A cumulative LC9 risk factor count (range 0–9) was calculated by summing adverse components, with higher counts indicating greater LC9 risk factor burden. Survey-weighted linear, logistic, and multinomial logistic regression models were used to estimate these associations, adjusting for potential confounders.</div></div><div><h3>Results</h3><div>Among 10 913 participants (mean age 28.4 years; 49.4 % male), 492 (4.7 %) reported an ADHD diagnosis. Over 9 years of follow-up, ADHD was associated with a higher LC9 risk factor count. Compared with individuals without ADHD, those with ADHD had higher odds of cigarette smoking (OR, 1.66 [95 % CI, 1.26–2.18]), sleep problems (OR, 1.41 [95 % CI, 1.09–1.82]), and anxiety and/or depression (OR, 3.31 [95 % CI, 2.50–4.42]). In joint-category analyses, participants with both ADHD and anxiety and/or depression showed the most adverse profiles, particularly for smoking, sleep problems, hyperlipidemia, and hypertension.</div></div><div><h3>Conclusions</h3><div>ADHD in young adulthood is associated with an unfavorable cardiovascular risk profile. Psychological comorbidity substantially amplifies this burden, highlighting the importance of integrating mental health screening into LC9-based cardiovascular prevention strategies.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101636"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statin use and cognitive outcomes in older adults","authors":"Raiza Rossi ,&nbsp;Mufti Mushfiqur Rahman ,&nbsp;Zafer Akman ,&nbsp;Laura T. Moreines ,&nbsp;Armin Nouri ,&nbsp;Mohammad Al Mouslmani ,&nbsp;Chidubem Ezenna ,&nbsp;Kaitlyn A. Stoehr ,&nbsp;Shefa Arya Nezhad ,&nbsp;Stephen Y. Wang ,&nbsp;Abdulla A. Damluji ,&nbsp;Michael G. Nanna","doi":"10.1016/j.ajpc.2026.101512","DOIUrl":"10.1016/j.ajpc.2026.101512","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101512"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of IL-6 inhibition on lipoprotein(a) levels: A systematic review and meta-analysis","authors":"Saeid Mirzai ,&nbsp;James McParland ,&nbsp;Muhammad Imtiaz Ahmad ,&nbsp;Emil deGoma ,&nbsp;John Walsh ,&nbsp;Michael D. Shapiro","doi":"10.1016/j.ajpc.2026.101498","DOIUrl":"10.1016/j.ajpc.2026.101498","url":null,"abstract":"<div><h3>Background</h3><div>Inhibition of interleukin (IL)-6 signaling by monoclonal antibodies (mAb) inhibits apolipoprotein(a) synthesis and reduces circulating lipoprotein(a) [Lp(a)] levels.</div></div><div><h3>Aims</h3><div>The aims of this systematic literature review and meta-analysis were to summarize clinical evidence for and quantify the effect of anti-IL­-6/IL-6 receptor (IL-6R) treatment on Lp(a) levels. Secondary inflammatory and lipid endpoints were also examined.</div></div><div><h3>Methods</h3><div>Searches were conducted using Embase, PubMed and Cochrane Library databases to identify studies reporting changes in Lp(a) levels following repeat doses of anti-IL-6/IL-6R mAbs. A random-effects meta-analysis compared the effect of IL-6 inhibition vs comparator on Lp(a) levels. A pre­-post analysis assessed the effect of IL-6 inhibition on Lp(a) levels before and after treatment. Subgroup analyses by disease type, IL-6 inhibition agent, and comparators were conducted.</div></div><div><h3>Results</h3><div>Out of 96 records, 10 studies with 1,201 participants were included. IL-6 inhibition was associated with significant reductions in Lp(a) levels vs baseline at 2–3 months (standardized mean difference [SMD] -0.29; 95% CI -0.44 to -0.14; <em>P</em> = .0002; I² = 33%) and 6 months (SMD -0.33; 95% CI -0.51 to -0.15; <em>P</em> = .0003; I² = 0%). Compared with tumor necrosis factor inhibitors or placebo, IL-6 inhibition showed greater Lp(a) reductions at 2–3 months (SMD -0.49; 95% CI -0.73 to -0.24; <em>P</em> = .0001; I² = 63%) and 6 months (SMD ­-0.97; 95% CI -1.16 to -0.77; <em>P</em> &lt; .00001; I² = 0%).</div></div><div><h3>Conclusions</h3><div>This meta-analysis demonstrates significant reductions in Lp(a) levels with anti-IL­-6/IL-6R therapy vs controls. The relevance of these findings warrants investigation in cardiovascular outcome trials.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101498"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of post-acute sequelae of COVID-19 on cardiac function and structure: A systematic review and a hybrid individual participant data meta-analysis","authors":"Binyam Tariku Seboka ,&nbsp;Lillian Ma ,&nbsp;Dianna J. Magliano ,&nbsp;Stella Talic ,&nbsp;Antonio da Silva Menezes Junior ,&nbsp;Alessandra Borlotti ,&nbsp;Helena Thomaides Brears ,&nbsp;Andrea Dennis ,&nbsp;Amitava Banerjee ,&nbsp;Thomas H. Marwick ,&nbsp;Quan Huynh","doi":"10.1016/j.ajpc.2026.101457","DOIUrl":"10.1016/j.ajpc.2026.101457","url":null,"abstract":"<div><h3>Background</h3><div>Post-acute sequelae of SARS-CoV-2 infection (PASC), also referred to as Long COVID, affect a significant proportion of COVID-19 survivors, with evidence suggesting cardiovascular involvement. However, the nature, extent, and clinical significance of these alterations remain uncertain.</div></div><div><h3>Aim</h3><div>To synthesize evidence on structural and functional cardiac alterations in individuals with PASC compared with those without PASC.</div></div><div><h3>Method</h3><div>We systematically searched seven databases. Random-effects meta-analyses were performed and supplemented by individual participant data (IPD) analyses from three studies. Univariable and multivariable meta-regressions examined associations with study-level characteristics. Publication bias and evidence certainty were assessed using standard methods (funnel plots, Egger’s test, trim-and-fill, and GRADE).</div></div><div><h3>Results</h3><div>From 3580 records, 17 studies with 4852 participants (3173 PASC, 1679 controls) met the inclusion criteria. IPD analysis revealed an impairment in global longitudinal strain (GLS) (mean difference (MD) = 3.63 %) in individuals with PASC. When using categorical thresholds, 58 % of individuals with PASC had GLS &lt; 16 %, indicating a significant prevalence of subclinical left ventricular dysfunction. Meta-analysis supported these findings, showing impaired GLS (MD = 1.07 %), along with reductions in left ventricular ejection fraction (MD = -1.30 %) and left ventricular end-diastolic volume (MD=-3.98 mL). Meta-regression showed that cardiac dysfunction was more frequently observed in individuals with older age, diabetes, and hypertension.</div></div><div><h3>Conclusion</h3><div>This review indicates that PASC is associated with modest, subclinical alterations in cardiac function. These alterations appear more pronounced in older adults and those with cardiometabolic comorbidities, highlighting the potential value of risk-stratified cardiovascular surveillance in individuals with PASC. The long-term clinical relevance of these changes remains unclear and warrants further study.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101457"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148195781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The next FRONTIER: Dedicated efforts to increase representative clinical trial enrollment","authors":"Ramzi Dudum,&nbsp;Jessica N. Holtzman","doi":"10.1016/j.ajpc.2026.101563","DOIUrl":"10.1016/j.ajpc.2026.101563","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"27 ","pages":"Article 101563"},"PeriodicalIF":5.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148196009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}